Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis
Acta Psychiatrica Scandinavica · 2025-05 · 151 (5) · 557-571
DOI: 10.1111/acps.13778 ↗At a glance
Systematische Übersicht in Acta Psychiatrica Scandinavica, published online on 2024-12-03. Written by Vikas Menon and 3 co-authors. Institution: Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. Major MEDLINE topics: Major Depressive Disorder, Psilocybin, Hallucinogens, Depressive Disorder, Treatment-Resistant. Cited 20 times so far (Crossref); 50 references.
Abstract (original language)
Introduction
There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including treatment‐resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates of change in depression ratings with PAT versus comparator treatments in MDD. We also compared response and remission rates, and adverse effects.
Methods
We searched MEDLINE, EMBASE, Cochrane Central Register for Controlled Trials (CENTRAL), and SCOPUS from inception till April 2024. Our primary efficacy outcome was 1‐week (or nearest) between‐group change in depression ratings. Secondary efficacy outcomes were changes in depression ratings at days 2, 14, and 42 (or nearest) and study‐defined response and remission rates at week 1 (or nearest). Safety outcomes were reported adverse effects. We pooled outcomes in random‐effects meta‐analyses using standardized mean difference (SMD; Hedges g ) for continuous outcomes and risk ratio (RR) for categorical outcomes.
Results
We found 6 eligible RCTs (pooled N = 427), all on psilocybin. The pooled SMD for 1‐week between‐group change in depression ratings was −0.72 [95% CI, −0.95 to −0.49; I 2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42. The response [RR = 3.42; 95% CI, 2.35–4.97; I 2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26–5.92; I 2 = 0%; 4 RCTs; n = 373] rates also favored PAT. The PAT group had a small but significantly increased risk of developing any adverse event [RR = 1.20; 95% CI, 1.01–1.42; I 2 = 43%; 4 RCTs; n = 373] and a significantly higher risk of experiencing headache [RR = 1.78; 95% CI, 1.10–2.86; I 2 = 52%; 4 RCTs; n = 373] and dizziness [RR = 6.52; 95% CI, 1.19–35.87; I 2 = 0%; 3 RCTs; n = 269]. Low heterogeneity characterized most analyses and findings were similar in sensitivity analyses.
Conclusion
Antidepressant effects of psilocybin‐assisted therapy are superior (with at least medium effect sizes) to comparator interventions for at least up to 6 weeks postintervention.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
- Department of Psychiatry, Pondicherry Institute of Medical Sciences, Puducherry, India.
- Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bengaluru, India.
ORCID profiles: Vikas Menon, Chittaranjan Andrade
Cite
APA
Menon, V., Ramamurthy, P., Venu, S., & Andrade, C. (2025). Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis. Acta Psychiatrica Scandinavica, 151(5), 557-571. https://doi.org/10.1111/acps.13778
Vancouver
Menon V, Ramamurthy P, Venu S, Andrade C. Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis. Acta Psychiatrica Scandinavica. 2025;151(5):557-571. doi:10.1111/acps.13778
BibTeX
@article{Menon2025,
author = {Menon, Vikas and Ramamurthy, Parthasarathy and Venu, Sandesh and Andrade, Chittaranjan},
title = {Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis},
journal = {Acta Psychiatrica Scandinavica},
year = {2025},
volume = {151},
number = {5},
pages = {557--571},
doi = {10.1111/acps.13778}
}
EUVIMED